%0 Journal Article
%T Telavancin for the treatment of nosocomial pneumonia caused by methicillin-resistant Staphylococcus aureus (MRSA)
%A Hooper CY
%A Smith WJ
%J Therapeutics and Clinical Risk Management
%D 2012
%I Dove Medical Press
%X Candace Y Hooper, Winter J SmithDepartment of Pharmacy, Clinical and Administrative Sciences, University of Oklahoma Health Sciences Center College of Pharmacy, Oklahoma City, OK, USAAbstract: Telavancin is a bactericidal lipoglycopeptide antibiotic that is structurally related to vancomycin. It demonstrates in vitro activity against a variety of Gram-positive pathogens including, but not limited to, methicillin-resistant Staphylococcus aureus (MRSA). Telavancin is currently FDA-approved for the treatment of complicated skin and skin-structure infections. Recently, two randomized clinical trials demonstrated the efficacy and safety of telavancin compared to vancomycin for the treatment of nosocomial pneumonia. Overall, telavancin has a favorable safety profile. However, mild gastrointestinal disturbances and reversible increases in serum creatinine were observed in clinical studies. Additional clinical studies are needed to evaluate telavancin¡¯s efficacy and safety in comparison to other antistaphylococcal agents for the treatment of infections such as bacteremia and endocarditis.Keywords: telavancin, MRSA, hospital-acquired pneumonia, health care-associated pneumonia, ventilator-associated pneumonia, nosocomial pneumonia
%U http://www.dovepress.com/telavancin-for-the-treatment-of-nosocomial-pneumonia-caused-by-methici-a9510